Relyvrio (US) / Albrioza (EU)

Drug Overview

Relyvrio was a prescription medication utilized within the Neurology specialty. It belonged to a unique class of neuroprotective agents designed as a combination of an Endoplasmic Reticulum Protectant and a Mitochondrial Protectant. As a specialized Targeted Therapy, it was designed to treat Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease. Rather than treating the symptoms, this drug was created to stop motor neurons from dying by protecting their internal power plants and protein-building factories.Relyvrio (US) / Albrioza (EU)

• Generic Name: Sodium phenylbutyrate and Taurursodiol (PB-TURSO)
  
• US Brand Names: RELYVRIO® (US), ALBRIOZA™ (Canada)
  
• Route of Administration: Oral (Powder for suspension mixed with water)
  
• FDA Approval Status: Granted accelerated FDA approval in September 2022. However, it was voluntarily withdrawn from the global market in April 2024 due to failed Phase 3 clinical trials. It is no longer available for commercial prescription.
  

What Is It and How Does It Work? (Mechanism of Action)

In ALS, the motor neurons (the nerve cells that control muscle movement) rapidly degenerate and die. Medical research suggests this cell death is heavily driven by two internal cellular failures: Endoplasmic Reticulum (ER) stress and mitochondrial dysfunction.

Relyvrio was designed as a dual-action Targeted Therapy combining two different molecules to rescue these failing cellular systems.

At the molecular and cellular levels, here is how the combination was intended to protect the nervous system:

• Sodium Phenylbutyrate (PB) and the ER: The endoplasmic reticulum (ER) is the cell’s factory for folding proteins. In ALS, proteins misfold and clump together, causing severe “ER stress.” Sodium phenylbutyrate acts as a chemical chaperone. It binds to these misfolded proteins and helps them fold correctly, turning off the cell’s internal distress signals and preventing the nerve from triggering its own death.
  
• Taurursodiol (TURSO) and Mitochondria: Mitochondria are the power plants of the cell. In ALS, they become leaky and lose their ability to produce energy. Taurursodiol (a bile acid) embeds itself in the mitochondrial membrane, stabilizing it. This prevents the power plant from breaking open and releasing toxic enzymes that cause cell death (apoptosis).
  
• Combined Cell Survival: By simultaneously fixing the protein factory and stabilizing the power plant, the drug aimed to keep motor neurons alive and functioning for a longer period.
  

FDA-Approved Clinical Indications

• Primary Indication: Amyotrophic Lateral Sclerosis (ALS). (Historical): Relyvrio was granted accelerated FDA approval to treat adults with ALS to slow the decline of daily physical functioning. (Note: As clarified above, it is no longer indicated or available for use due to its 2024 market withdrawal. It was never approved for neuropathic pain or migraines).
  
• Other Approved Uses:
  • 
    The combination drug (PB-TURSO) has no other approved medical uses.
    
  • Individual components: Sodium phenylbutyrate alone is approved to treat rare urea cycle disorders. Taurursodiol is used in some regions for liver and gallbladder diseases.
    

Dosage and Administration Protocols

(Historical Dosage Guidelines prior to withdrawal)

Relyvrio was supplied as a powder in single-dose packets. It had to be mixed with 8 ounces of room-temperature water and stirred vigorously before swallowing or administering through a feeding tube.

Dose Adjustments

• High Sodium Content Warning: Each packet contained 464 mg of sodium (nearly 1,000 mg per day at the maintenance dose). Patients with heart failure, severe hypertension, or renal impairment required strict cardiovascular monitoring due to the risk of severe fluid retention.
  
• Hepatic and Enterohepatic Circulation Disorders: Taurursodiol is a bile acid. The drug was not recommended for patients with severe liver disease, biliary blockages, or severe intestinal malabsorption, as these conditions prevent the drug from being processed properly.
  

Clinical Efficacy and Research Results

The clinical journey of Relyvrio serves as a major case study in modern neurology (2020–2026), highlighting the difference between Phase 2 promise and Phase 3 reality.

• Initial Promise (Phase 2 CENTAUR Trial): The drug received its 2022 accelerated FDA approval based on a 137-patient Phase 2 trial. In this small study, patients taking Relyvrio scored an average of 2.32 points higher on the ALS Functional Rating Scale (ALSFRS-R) over 6 months compared to a placebo. Long-term tracking suggested a median survival benefit of approximately 6.5 months.
  
• Phase 3 Failure (PHOENIX Trial – 2024): To confirm these findings, a massive, global Phase 3 trial was conducted with over 600 patients. In March 2024, the results were published, showing that the drug failed entirely. There was zero statistically significant difference between Relyvrio and the placebo in slowing physical decline (ALSFRS-R scores), nor did it improve survival, breathing function, or muscle strength.
  
• Market Withdrawal: Due to the clear lack of clinical efficacy in the Phase 3 data, the manufacturer voluntarily withdrew the drug from the market globally in April 2024.
  

Safety Profile and Side Effects

Black Box Warning: Relyvrio did not carry a formal FDA “Black Box” warning, but its label contained prominent warnings regarding its high sodium content and bile acid-related gastrointestinal toxicity.

Common Side Effects (>10%)

• Gastrointestinal Distress: Diarrhea, abdominal pain, nausea, and excessive saliva production were the most common reasons patients stopped taking the drug.
  
• Upper Respiratory Tract Infections: Common colds and sinus congestion.
  
• Fatigue: Feeling unusually tired or weak.
  

Serious Adverse Events

• Cardiovascular Overload: Because of the nearly 1,000 mg of extra daily sodium, vulnerable patients could experience dangerous spikes in blood pressure, severe ankle swelling, or worsening of congestive heart failure.
  
• Bile Acid Toxicity: In patients with pre-existing liver or gallbladder issues, the bile acid component could worsen liver inflammation or cause severe diarrhea leading to dehydration.
  

Management Strategies

• Managing the Taste and Stomach Upset: The medication was notoriously bitter and foul-tasting. Patients were advised to take it just before eating a meal to help mask the taste and settle the stomach.
  
• Sodium Management: Dietitians often had to help patients severely restrict sodium in their food to balance the massive sodium load coming from the medication itself.
  

Connection to Stem Cell and Regenerative Medicine

In the advancing field of regenerative neurology, solving the problem of a toxic cellular environment is required before the nervous system can be repaired. Although Relyvrio ultimately failed to slow ALS, the biological theory behind it—fixing the endoplasmic reticulum and mitochondria—remains a cornerstone of cellular research. As a Targeted Therapy, it aimed to create a healthier, less toxic environment (a “niche”) in the spinal cord. Current medical research (2024–2026) still investigates how metabolic preconditioning acts as a biological shield. Scientists believe that if they can successfully stabilize the local environment using similar cellular protectants, newly implanted regenerative therapies (like mesenchymal stem cells) will have a much higher chance of surviving and repairing the damaged motor neurons without being instantly destroyed by toxic cellular stress.

Patient Management and Practical Recommendations

(Note: These reflect the historical management practices when the drug was actively prescribed).

Pre-Treatment Tests

• Cardiovascular Screening: Baseline blood pressure and heart failure assessments due to the high sodium content.
  
• Hepatic Panel: Baseline liver function tests (AST, ALT, bilirubin) to ensure the liver and bile ducts were healthy enough to process the medication.
  

Precautions During Treatment

• Dietary Sodium: Patients had to be highly vigilant about reading food labels to avoid eating excess salt, preventing dangerous fluid buildup in the lungs or legs.
  
• Feeding Tube Care: If given through a PEG tube, the tube had to be flushed with water immediately after the dose to prevent the sticky suspension from clogging the line.
  

Do’s and Don’ts

• DO vigorously stir the powder into 8 ounces of water until it is mostly dissolved.
  
• DO take the medication right before a snack or meal to help reduce nausea and hide the bitter taste.
  
• DO monitor your blood pressure regularly at home.
  
• DON’T mix the powder with juice, milk, or hot liquids, as this changes how the drug is absorbed.
  
• DON’T ignore sudden swelling in your ankles or a sudden inability to catch your breath, as this could mean the sodium load is affecting your heart.
  

Legal Disclaimer

The information provided in this medical guide is for educational, historical, and informational purposes only and does not replace professional medical advice. Relyvrio (Albrioza) was officially withdrawn from the commercial market in 2024 due to a lack of clinical efficacy in Phase 3 trials and is no longer available as an ALS treatment. Patients currently seeking ALS therapies should consult with a licensed healthcare professional or an ALS specialist regarding currently approved, evidence-based diagnosis and treatment options appropriate for their individual medical needs.